Text Size

Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials

This study has been completed.
Sponsor:
Collaborator:
Ludwig-Maximilians - University of Munich
Information provided by:
Faculty of Medical Sciences Jimma University
ClinicalTrials.gov Identifier:
NCT00451139
First received: March 21, 2007
Last updated: March 22, 2007
Last verified: March 2007
History of Changes
  Purpose

The purpose of the study is to evaluate the potential side-effects of artemether / lumefantrine and other antimalarials on the auditory function.


Condition Intervention Phase
Malaria
 Drug: artemether/lumefantrine
Drug: quinine
Drug: atovaquone/proguanil
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label

Resource links provided by NLM:

MedlinePlus related topics: Malaria
U.S. FDA Resources

Further study details as provided by Faculty of Medical Sciences Jimma University:

Detailed Description:

Artemisinin based combination therapies (ACT) currently are the most promising treatment options for uncomplicated falciparum malaria. There have been controversial reports about possible ototoxicity of artemether / lumefantrine (Coartem®) from retrospective studies. In this investigation treatment of uncomplicated malaria with artemether / lumefantrine, quinine, where side-effects on hearing are known, or atovaquone / proguanil, where no such effects have been reported, are compared. Auditoy function is examined (Auditory Brainstem Response, Pure-tone Audiometry, Otoacustic Emissions) before treatment, after 7, 28, and, for determination of irreversibility, after 90 days.

  Eligibility

Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patients aged above 5 years
  • Uncomplicated falciparum malaria
  • Axillary Temperature ≥37,5°C or history of fever within the previous 24 hours
  • Ability to tolerate oral therapy
  • Informed consent by the patient or by parent/guardian for children
  • Residence in study area

Exclusion Criteria:

  • Known or suspected hearing deficits
  • Adequate anti-malarial treatment within the previous 7 days
  • Mixed infection
  • Danger signs and signs of severe malaria as defined by the WHO
  • Presence of severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known HIV infection)
  • Concomitant disease masking assessment of response
  • History of allergy or intolerance against study medications
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00451139

Locations
Ethiopia
Jimma University Hospital
Jimma, Ethiopia
Sponsors and Collaborators
Faculty of Medical Sciences Jimma University
Ludwig-Maximilians - University of Munich
Investigators
Study Chair: Nebreed Fesseaha, MD, Dean Facuty of Medical Sciences Jimma University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00451139     History of Changes
Other Study ID Numbers: AITM0107
Study First Received: March 21, 2007
Last Updated: March 22, 2007
Health Authority: Ethiopia: Ethiopia Science and Technology Commission

Additional relevant MeSH terms:
Malaria
Protozoan Infections
Parasitic Diseases
Antimalarials
Proguanil
Quinine
Artemether
Atovaquone
Lumefantrine
Malarone
Artemether-lumefantrine combination
Artemisinins
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
 Therapeutic Uses
Pharmacologic Actions
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Muscle Relaxants, Central
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Antifungal Agents
Coccidiostats
Schistosomicides

ClinicalTrials.gov processed this record on May 19, 2013